Are you a Young Investigator with a recent publication in JHEP or JHEP Reports? We want to hear from you!
Have you published an article in either journal within the past 12 months as the first or corresponding author? This is your opportunity to showcase your research through our YI Paper of the Month initiative!
We invite Young Investigators to present their work and share their findings with the wider EASL Young Investigator community.
How to get involved?
Simply email us at [email protected] and send us:
🎥 A short video (maximum 1 minute), recorded in front of a green screen or plain wall, including:
• A brief introduction of yourself.
• A short presentation of your article and its key findings.
📄 Your supporting information:
• Proof of your Young Investigator status (Trainee members can simply provide their membership ID).
• A link to your published article.
Why take part?
Showcase your research, share your findings with fellow Young Investigators, and give your work greater visibility across the EASL community! We look forward to featuring your research!
massimo iavarone retweeted
🚨 Calling UK & International hepatologists with a PhD
Ready to take the next step towards becoming an independent clinical academic?
Join us at King's.
🔬 Up to 3 years of funded postdoctoral research with clinical opportunities.
📅 Apply by 17 Dec 2026
massimo iavarone retweeted
Intercontinental panel at @BCLC_group update to discuss treatment options for #HCC in 2026 @MarcoSanduzzi @NaultJc @massimoiava and many others
massimo iavarone retweeted
#EPATOLOGIA L'expertise nella cura delle malattie del #fegato di #PoliclinicoMi al centro del convegno “Epatopatia avanzata: dalla gestione dello scompenso alle nuove indicazioni al trapianto”, organizzato dal prof. Pietro Lampertico, direttore Gastroenterologia ed #Epatologia
massimo iavarone retweeted
New @EASLnews Talk Liver To Me podcast: “CCA Surveillance in Patients with PSC” 🎧
Status quo, recommendations, current tools & next promising biomarkers. Much still to do, but the horizon looks promising.
With @DebbieShawcros1 & @ Gideon Hirschfield
easlcampus.eu/tltm/episode-2…
💙 Putting people at the heart of liver care deserves recognition!
The 2027 EASL Excellence in Liver Care Award celebrates liver nurses and Allied Health Professionals who go above and beyond to improve patient care and outcomes.
🌟 Know someone making a difference? Nominate them, or yourself!
📅 Deadline: 24 November 2026
📩 Send nominations to [email protected]
🔗 Find out more: easl.eu/easl/leadership-and-…
massimo iavarone retweeted
💁🏻♂️ Check out our new paper on FMT plus IO in IO-refractory HCC @NatureComms
@aktibes @BernharScheiner @GI_Baumgartner @balcar_lorenz @NurseJudy11
#OncTwitter #LiverTwitter #HCC
nature.com/articles/s41467-0…
massimo iavarone retweeted
Today ushers in the era of #HBV functional cure with @FDA approval of #bepirovirsen branded by @GSK as #hibsago
A lot to digest regarding administration, efficacy, safety monitoring & scalability but for the 270 mil w/ HBV, finite rx is no longer aspirational
#livertwitter
FDA approved a new first-in-class treatment for certain adults with chronic hepatitis B virus (HBV) infection. fda.gov/news-events/press-an…
For some patients, it may allow viral control even after stopping all HBV therapy, a major step forward for a disease that often requires lifelong treatment.
massimo iavarone retweeted
🇪🇺🎗️ OCTOBER | #LiverCancerAwarenessMonth
#HEPATITIS D: THE HIDDEN THREAT WE CAN NO LONGER AFFORD TO MISS.
EVERY PERSON LIVING WITH HEPATITIS B SHOULD BE TESTED FOR HEPATITIS D.
🦠 #Hepatitis D (#HDV) cannot exist without #hepatitis B (#HBV). Yet too many people living with HBV have never been tested for HDV.
This is one of the most important missed opportunities in viral hepatitis care across Europe.
HDV is associated with one of the most aggressive forms of chronic viral hepatitis, accelerating liver damage and increasing the risk of:
🔴 Cirrhosis and liver failure
🎗️ Hepatocellular carcinoma (HCC) — liver cancer
🫀 Liver transplantation
⚠️ Premature mortality
And the greatest concern? People may remain unaware of their infection until serious complications develop.
💊 THE TREATMENT LANDSCAPE IS CHANGING.
For years, treatment options for hepatitis D were extremely limited.
Today, innovative therapies such as bulevirtide, authorised in the European Union for eligible patients with chronic HDV, are creating new opportunities to control infection and improve clinical outcomes.
Other therapeutic approaches are also being investigated.
We are entering a new era in hepatitis D care — but innovation means little if patients are never diagnosed.
🔎 ONE TEST CAN CHANGE THE PATHWAY.
International recommendations support anti-HDV testing for everyone who is HBsAg-positive, with HDV RNA testing to confirm active infection when indicated.
We should not wait for unexplained liver deterioration, advanced fibrosis or cirrhosis before considering HDV.
Test for HBV.
If HBV-positive, test for HDV.
If HDV-positive, confirm active infection.
Assess liver damage.
Link patients to specialist care and appropriate treatment.
🇪🇺 EUROPE HAS AN OPPORTUNITY TO ACT.
But we need more than separate initiatives.
We need:
✅ Routine HDV testing integrated into HBV care pathways across Europe.
✅ Greater awareness among healthcare professionals and patients.
✅ Equitable access to confirmatory diagnostics, specialist care and innovative treatments.
✅ Stronger connections between viral hepatitis programmes, liver cancer surveillance and transplantation services.
✅ National implementation that reduces inequalities between European countries.
HDV is often described as a rare infection. But how can we understand its true burden when so many people with hepatitis B have never been tested?
🎗️ DON'T WAIT FOR LIVER CANCER TO START LIVER CANCER PREVENTION.
We have the diagnostic tools.
We have new treatment opportunities.
We have recommendations.
Through the European Liver Screening Tour and European Liver Screening Week. ELPA continues advocating for earlier detection and better connections between prevention, treatment and long-term liver health.
🇪🇺 European Liver Screening Tour 2026
🇪🇺 #EUScreeningWeek | #EuropeanLiverScreeningWeek
🎗️ #LiverCancerAwarenessMonth
massimo iavarone retweeted
🎙️Discover the New #TalkLiverToMe episode on Resmetirom and Semaglutide as MASH-targeted therapies!
@JHepatology @DebbieShawcros1 @Tacke_lab @gastaldelli_amy @EASOobesity @EASDnews
#LiverX
In this new episode of #TalkLiverToMe, experts discuss the practical use of resmetirom and semaglutide, based on the 2026 EASL–EASD–EASO Guidance.
Who should be treated, when should therapy start, and how should response be monitored?
Listen on EASL Campus: easlcampus.eu/tltm/episode-1…
Also on Spotify: open.spotify.com/episode/4Wt…
and Apple Podcasts: podcasts.apple.com/ch/podcas…
massimo iavarone retweeted
Everything you need to know about liver biopsy!
The first @AASLDtweets EXPO is on biopsy and it is online now without paywall: ovid.com/jnls/hep/fulltext/1…
massimo iavarone retweeted
#Baveno VIII consensus in portal hypertension #CSPH
Full Consensus Report now @JHepatology @EASLnews
journal-of-hepatology.eu/art…
massimo iavarone retweeted
🔵 HCC Interventional Therapy Series | Part 1
Can combining locoregional and systemic therapies improve outcomes in liver cancer?
Discover how individualized combination strategies can translate into meaningful clinical benefit
📖 oaepublish.com/articles/2394…
#HCC #LiverCancer
massimo iavarone retweeted
📌 Il webinar “AISF practice guidance on the treatment of primary biliary cholangitis: a 2026 update” approfondirà le indicazioni contenute nell'aggiornamento 2026 della Practice Guidance AISF.
📅 21 ottobre 2026
🕕 ore 18.00
👉 Iscriviti al webinar
aristea.online/events/aisfwe…
massimo iavarone retweeted
💡 Complete pathologic response (cPR) is linked to better survival after #LT for #HCC @AnnalsofSurgery
👉 Imaging-pathology concordance was poor (30.5%), with imaging overestimating response in 42.6%.
👉 cPR higher with Y-90 (41.2%) and ablation (36.4%) vs TACE (24.0%).
👉 cPR vs no cPR: 5-yr OS 86.6% vs 77.4%, RFS 76.9% vs 63.1%.
DOI: doi.org/10.1097/SLA.00000000…
@AASLDtweets @ASCO @AACR #LiverX #UNOS
massimo iavarone retweeted
🎉 Congrats to @PinterMatthias and @DJPinato on this #HCC study!
💡 #CTP & #ALBI stay prognostic in non-cirrhotic #HCC @JHEP_Reports
👉 443 non-cirrhotic pts from 2 cohorts (BCLC A-C, and Atezo/Bev or Durva/Treme)
👉 CTP-B and higher ALBI grade independently linked to worse OS
👉 Prognostic accuracy comparable to HCC with cirrhosis
DOI: doi.org/10.1016/j.jhepr.2026…
@ILCAnews @EASLnews @myESMO
Prognostic role of the Child-Turcotte-Pugh classification and ALBI grade in patients without cirrhosis and hepatocellular carcinoma
sciencedirect.com/science/ar…
massimo iavarone retweeted
Thank you @PrecisionBTCnet @rirmacias for supporting the open access publication of this international collaborative effort on #targeted therapies following #chemoimmunotherapy in #BTC
@casadei_gardini @MargheRimini and many others @JHepatology
massimo iavarone retweeted
🆕🔥🟢Just published by @ebtapper et Al
ACG Clinical Guideline: Preventive Care for Patients With Cirrhosis #idxposts
journals.lww.com/ajg/fulltex…
massimo iavarone retweeted
#BavenoVIII – @BavenoCoop
out in @JHepatology
Advancing consensus in portal hypertension
journal-of-hepatology.eu/art…
massimo iavarone retweeted
Congratulations to Amit Singal, M.D., on his election as President-Elect of the International Liver Cancer Association!
Dr. Singal will serve as President-Elect in 2027 and ILCA President from 2028–2029, helping advance liver cancer prevention and treatment. @docamitgs @ILCAnews












































